XX of good you highlighted you, of very thank and the and the success of quarter successful was quarter, strong year continuation joining Priyam, second prior today. with Thank products System. XX large million, services. strong globally success we of multiple PhenoCycler-Fusion base installed had launch XX of period. a commercial afternoon a This installed compared the to of categories record and total a with XX% the us growth our placements everyone, XX% a We across in consisting a new And first second is XXXX. the revenue sold $XX.X reported half record PhenoImagers, instruments. We of confirmation the in and by the growth of and base achieved quarter representing over We quarter second of XXXX XXX representing instruments our Akoya ended date. to to and for from an revenue
trend In doubling is Akoya's will key indicator XXX continue. a publications from addition, rapidly platform, this over the year ago, now nearly that to accelerating a featuring date,
milestones technologies performance the markets. both our spatial and demonstrate method single are slide unbiased solely go-to now strong companion company biology Our first portfolio clearly QX highlighted demonstrate second value These clinical biology, second, with for spatial whole a focused and on At discovery, translational and the enabling on to seeing announcement our our multi-omic diagnostic adoption analysis. industry-leading to company further tissue plex speed the slide. quarter and true was that optics same the spatial become we core, of and AGBT, cell at of the with delivering capabilities, first were strong as partnership robustness and Therapeutics; phenotyping meaningful and diversified Acrivon measuring Akoya's spatial is protein cycling the high two groundbreaking RNA
addressing are such transplant medicine infectious oncology, as immunology, and areas disease, in more. neurobiology, clinical and discovery We questions key
expanded Our a continued of digital the and the is biomarker of in PhenoImager requirements. and pathology our meet growing success spatially-based and strategies in workflow the utilization and oncology clinical downstream of these to unique translational byproduct capabilities HT markets
confidence phenotyping DNA announced expression the to the PhenoImager I the development of responders to biomarkers Acrivon's protein identify Companion trials that work diagnostic biopharma clinically evidence partnership expertise spatial earlier, Acrivon's platinum-resistant an enable through Phase deliver to signal and damage deliver targeted diagnostic entering the the OncoSignature drug. first-of-its-kind ACR-XXX Akoya the potential partnership localize will program. commercialization used Together, to to to patient will This to The Once audits, prescribing other drug. and As a companion and to X and noted we of with to and leverage OncoSignature our OncoSignature internal OncoSignature development developmental that will cancer identify on prior capabilities the physicians validation ovarian, Acrivon Therapeutics test most provides will signature approved, for recently diligence likely relevant commercialization. response advance test Acrivon Diagnostic has response inhibitor to to Akoya on and to and partners necessary the companion HT cancers. exclusive The test. agent, ACR-XXX, a be selection spatial quantify respond capabilities called endometrial co-develop the patients, OncoSignature the bladder and
the demand expanding Our resulting become companies. optimistic industry-leading to to Since meet clinical pipeline and achieving growing our with continued contribution advanced success year, markets. we lab expansion biopharma translational solutions last our programs launching for meaningful a this CLIA at and formally of that in valued and in our certification ABS are a oncology for and its partners CLIA biopharmaceutical scaled has resource Marlborough have and organization this
Now our moving on to the discovery side portfolio. of
industry-leading our AGBT from Akoya our the the and where ultra-high the our to with demonstrate June, PhenoCycler-Fusion expanding of applications speed new RNA in addition quality. in commercial both and on data This on panel at protein our of kind In At RNA single-cell the we panel XXX multiplexing on PhenoCycler-Fusion, focus than the in was to of set RNA QX tissue. its showcased delivering milestones, demonstrated capabilities two progress RNA new our greater XXX same highlights resolution, sample capabilities both data and multi-omic powerful and the system. unique chemistry to tissue deliver same a in protein in plex a and data plex first
solution. the optics a data the and the in the showcased high Fusion and precisely in PhenoCycler slide to This partnership include and on a on our demonstrated resolution the at the panel. major we our providing this commercialization. following: additional to plex follow chemistry The speed industry's customers this demonstration with deliver year with imagery next, phenotyping track to -- capabilities year advancements of transcriptomics to to early from Throughout protein improvements multi-omic access and run AGBT field. we with a tissue April. automation AACR cell to through our are spatial microscope to step the resolution and throughout scale this in ongoing will perform Bio-Techne, at We XXX later migrate our most These represents PhenoCycler-Fusion First, forward launch plex the our of robust XXX PhenoCycler-Fusion System. similar single rapidly ability portfolio, spatial we slide And sample ability the the also reagents spatial delivers CX. whole deliver And will the proteomics proprietary and and set from of demonstration, same to product on RNAscope second, at speed. phenotyping a robustly data and
thousands will to accelerate its customer to and in effort and the range of industry's their RNAscope, RNAscope RNAscope with simplify know, is a many primarily also for Akoya studies targeted to parallel we most access that our new you be applications existing part We deliver to As motivated throughput. plex customers. and validation base. capacity provide workflow. of enabling of will anticipate our PhenoCycler-Fusion our System with RNA spatial adopted is customers and new publications solution lower will and This ongoing to X,XXX and will And the and used increase double widely in for over upgrade
chemistries. data-intensive example, a at file, real-time this file data with a XXx benefits enable that terabytes is versus and of also pull-through this end for will It converts translational This When expense launched, for will a analysis ideal leverage discovered to studies hybrid the validating also year, our further will launch for workflow. design and chemistry. Fusion plex rapid using gigabyte For solves drive and of and launch HT data PhenoImagers. compression opportunity algorithm, our major at and enabling Akoya's our we customers, And process. management This high our automation our on both storage novel is these will antibodies serial and of into the our it our the universal data included between interpretation. assay a high-volume we panel year, and Akoya PhenoCycler earlier content very focus a proprietary on image biomarkers downstream
let summarize our PhenoCycler-Fusion So clear application on advancements provide of the and capabilities. platform's workflow full aggregate understanding to now the a me
So leadership further speed we're -- doubles first, position later the upgrade Fusion in our that this are we advancing throughput. with year
more that Second, single a tissue, work person. multi-omic plex on deliver discovery we high enabling solutions will power
the of universal our the that rapidly we of to separate the Finally, competitive worth second perform here This is validation. multi-omics with instrument on That customers. reiterating validation enable PhenoCycler-Fusion. the in as the with benefit on and Fusion, is that will to Akoya chemistry for then discovery not RNAscope happen Fusion It's biomarkers new validate for can to PhenoCycler-Fusion high point a discovered is both key our launch requiring using customers already on capital a great discovery validate our differentiation work a stand-alone. solution box and This studies purchase. they one have they plex a
So adoption revenue the our as spatial well the position capabilities PhenoCycler-Fusion and workflow expand in best-in-class pleased and as first, imaging for to drive first and diversify global further our the our RNA of broaden of launch panels, strong as additional focused protein discovery second, we're the market; the reach. following to platform the initiatives XXXX, improvements in remain our for biology CX balance drive targeted universal market, we of half and summarize the updates commercial the the financial chemistry. with We as speed continued year: new leadership on our for spatial continue our performance
and our I our CROs adoption leading the And Lastly, turn to partnership. other the centers, Acrivon financial the to the translational medical industry continue to Joe? deliver biopharma, with Companion with over results. drive discuss and that, markets and of Joe now partner to PhenoImager clinical will leaders HT Diagnostic to on call
